Cargando…

Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL

Detalles Bibliográficos
Autores principales:	Byrd, John C., Smith, Stephen, Wagner-Johnston, Nina, Sharman, Jeff, Chen, Andy I., Advani, Ranjana, Augustson, Bradley, Marlton, Paula, Commerford, S. Renee, Okrah, Kwame, Liu, Lichuan, Murray, Elaine, Penuel, Elicia, Ward, Ashley F., Flinn, Ian W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2019
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6557200/ https://www.ncbi.nlm.nih.gov/pubmed/31217910 http://dx.doi.org/10.18632/oncotarget.27011

Ejemplares similares

First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL
por: Byrd, John C., et al.
Publicado: (2018)

Second Cancer Incidence in CLL Patients Receiving BTK Inhibitors
por: Bond, David A, et al.
Publicado: (2020)

PI3k Inhibitors in NHL and CLL: An Unfulfilled Promise
por: Bou Zeid, Naji, et al.
Publicado: (2023)

Differential regulation of CTLA4 expression through BTK-dependent and independent mechanisms in CLL
por: Yano, Max, et al.
Publicado: (2022)

Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes
por: Hyak, Jonathan M., et al.
Publicado: (2022)

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance
por: Naeem, Aishath, et al.
Publicado: (2022)

Selecting the optimal BTK inhibitor therapy in CLL: rationale and practical considerations
por: Lovell, Alexandra R., et al.
Publicado: (2022)

Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities
por: Frustaci, Anna Maria, et al.
Publicado: (2023)

Idelalisib: The First-in-Class Phosphatidylinositol 3-Kinase Inhibitor for Relapsed CLL, SLL, and Indolent NHL
por: Forcello, Nicholas, et al.
Publicado: (2014)

Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL
por: Sharma, Shruti, et al.
Publicado: (2016)

BTK inhibitors impair humoral and cellular responses to recombinant zoster vaccine in CLL
por: Pleyer, Christopher, et al.
Publicado: (2022)

Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition
por: Lew, Thomas E., et al.
Publicado: (2021)

Circulating versus cellular tumor DNA for the detection of BTK resistant CLL clones
por: Trummer, Arne, et al.
Publicado: (2022)

BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib
por: Bonfiglio, Silvia, et al.
Publicado: (2023)

GDC respond to crisis
Publicado: (2020)

Mentoring, performance and the GDC
por: Saw, Mabel, et al.
Publicado: (2021)

First report of the unique expression of RECAF (receptor for alfa feto-protein) in adult B-NHL/CLL patients
por: Sedky, Hebatallah Adel, et al.
Publicado: (2020)

BTK inhibitors and anti-CD20 monoclonal antibodies for treatment-naïve elderly patients with CLL
por: Rogers, Andrew, et al.
Publicado: (2020)

The Nanomechanical Properties of CLL Cells Are Linked to the Actin Cytoskeleton and Are a Potential Target of BTK Inhibitors
por: Sampietro, Marta, et al.
Publicado: (2023)

GDC announces new chair
Publicado: (2021)

Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance
por: Blombery, Piers, et al.
Publicado: (2022)

High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL
por: Chiodin, Giorgia, et al.
Publicado: (2022)

Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice
por: O’Brien, Susan M., et al.
Publicado: (2021)

Biomarkers in NHL
por: Malek, Sami N.
Publicado: (2011)

Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors
por: Thompson, Ella R., et al.
Publicado: (2022)

Use of BTK Inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Practical Guidance
por: St-Pierre, Frédérique, et al.
Publicado: (2022)

Detection of Hepatocyte Growth Factor (HGF) Ligand-c-MET Receptor Activation in Formalin-Fixed Paraffin Embedded Specimens by a Novel Proximity Assay
por: Dua, Rajiv, et al.
Publicado: (2011)

Anti-CD79B Antibody–Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study
por: Herrera, Alex F., et al.
Publicado: (2022)

Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting
por: Mhibik, Maissa, et al.
Publicado: (2023)

Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

GDC 2: Compression of large collections of genomes
por: Deorowicz, Sebastian, et al.
Publicado: (2015)

GDC publishes 2019 fitness to practise statistics
Publicado: (2020)

GDC statement on complaints during the pandemic welcomed
Publicado: (2022)

GDC calls for DCPs to check CPD records
Publicado: (2022)

GDC calls for DCPs to check CPD records
Publicado: (2022)

CLL-211 Humoral Immune Response Following COVID-19 Vaccination in Patients With Chronic Lymphocytic Leukemia (CLL) and Indolent Non-Hodgkin Lymphoma (NHL): Results From a Large, Single-Center Observational Study
por: St-Pierre, Frédérique, et al.
Publicado: (2022)

Proteolysis Targeting Chimeras for BTK Efficiently Inhibit B-Cell Receptor Signaling and Can Overcome Ibrutinib Resistance in CLL Cells
por: Shorer Arbel, Yamit, et al.
Publicado: (2021)

Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study
por: Terpos, Evangelos, et al.
Publicado: (2021)

Poor Neutralizing Antibody Responses in Patients with CLL, NHL and HL after Vaccination Against Sars-Cov-2; A Prospective Study in 132 Patients
por: Terpos, Evangelos, et al.
Publicado: (2021)

0853. Elevated levels of soluble rage predict impaired alveolar fluid clearance in a translational mouse model of acute respiratory distress syndrome (ARDS)
por: Blondonnet, R, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_rro5qaejukum352ft4sm0bjj3k